UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3] - The company is currently developing and commercializing products for pulmonary hypertension and other applications using its proprietary PRINT Technology [3] Product Development - Liquidia's lead candidate is YUTREPIA™ (treprostinil) inhalation powder, which is an investigational drug aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3] - The company is also working on L606, an investigational sustained-release formulation of treprostinil that is administered twice daily with a next-generation nebulizer [3] - Additionally, Liquidia markets a generic version of Treprostinil Injection for the treatment of PAH [3] Upcoming Events - Liquidia will present an overview of its business at the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, at 8:45 a.m. ET [1] - Access to a webcast of the presentation will be available on the "Investors" page of Liquidia's website, with an archived version accessible for at least 30 days post-event [2]